Skip to main content
Clinical Trials/NCT00980707
NCT00980707CompletedPhase 4

Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma

Associated Scientists to Help Minimize Allergies1 site in 1 country10 target enrollmentStarted: August 2009Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
10
Locations
1
Primary Endpoint
Compare hyaluronan and versican in asthmatics versus atopic non-asthmatics.

Study Overview

Brief Summary

The purpose of this study is to determine the role of versican and hyaluronan measurements in induced sputum as biomarkers of asthma. Enroll 10 subjects with mild persistent asthma who are not receiving treatment with a controller therapy.

Detailed Description

We will compare spirometry, eNO and sputum measurements of versican and hyaluronan before and after treatment with fluticasone 220 ug/bid.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to 45 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Allergic asthma defined as a positive methacholine challenge

Exclusion Criteria

  • Non-atopic patients

Arms & Interventions

inhaled corticosteroid

Experimental

All asthmatics will start inhaled corticosteroids.

Intervention: Inhaled corticosteroid (fluticasone) (Drug)

Outcomes

Primary Outcomes

Compare hyaluronan and versican in asthmatics versus atopic non-asthmatics.

Time Frame: 1 year

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Associated Scientists to Help Minimize Allergies
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials